Pragmatic Trials: Bridging the Gap Between Research and Real-World Healthcare
"How Focusing on Clinical Reality Can Improve Healthcare Outcomes"
For nearly seventy years, randomized controlled trials (RCTs) have been the gold standard in medical research for evaluating the effectiveness of interventions. However, while RCTs excel at establishing internal validity—ensuring that the intervention itself causes the observed effect—concerns about their external validity, or generalizability to real-world clinical settings, have persisted. This has prompted a growing interest in research methodologies that better accommodate the complexities of clinical practice.
Enter pragmatic trials, also known as 'management trials.' These trials are designed with a primary focus on external validity, aiming to assess how well an intervention works in routine clinical practice. The concept isn't new; it was introduced half a century ago. Yet, its importance has only grown as researchers and healthcare professionals seek to bridge the gap between research findings and practical application.
The key is not to abandon the rigor of RCTs but to tailor the design to address specific research objectives. The PRECIS (PRagmatic Explanatory Continuum Indicator Summary) tool has been developed to help researchers align their trial design with their intended question, whether that question is primarily explanatory (focused on understanding mechanisms) or pragmatic (focused on real-world effectiveness).
Growing Use and Practical Impact
Pragmatic clinical trials are designed to capture diverse patient populations, support efficient follow-up, and reflect routine clinical practice. A 2025 review reported that the design features and use of real-world data in these trials remain insufficiently understood. Nature Index tracks the number of articles on pragmatic approaches in clinical trials across all publications by year, indicating sustained interest in the field. A September 2026 JAMA article noted that more than 40 trials labeled pragmatic by their investigators were published between January and June 2026, while also emphasizing that no universally accepted definition exists.
Design Strengths and Constraints
Pragmatic trials are evaluated according to the contexts in which their design is attractive or less suitable, rather than through a single universally applicable method. The New England Journal of Medicine identifies strengths, limitations, and implementation challenges as central considerations. The Mayo Clinic Proceedings reports that pragmatic clinical trials are increasingly popular, with their growth driven by factors beyond the limitations of explanatory trials. These observations suggest that pragmatic design is a context-dependent approach rather than a replacement for controlled explanatory research.
From Concept to Mainstream Attention
Pragmatic clinical trials can be randomized or nonrandomized and may have different degrees of pragmatic and explanatory power depending on their design. Randomization is preferable when it is practicably available, according to the cited overview. The field has gained substantial attention in the past decade: a 2024 JAMA article reported that more than 80% of National Library of Medicine citations identified by searching “pragmatic clinical trials” were published during the preceding 10 years. This marks a period of rapid growth rather than a single foundational discovery.
Making Trials More Relevant: Key Considerations for Pragmatic Design
Several design choices distinguish pragmatic trials from more traditional RCTs. These choices revolve around ensuring that the trial reflects the realities of clinical practice:
- Intervention Contrast: Compare new interventions to existing standards of care, not just placebos.
- Clinical Spectrum: Ensure the trial includes a diverse patient population that reflects the range of patients seen in clinical practice.
- Patient-Centered Outcomes: Focus on outcomes that are meaningful to patients, such as pain relief, functional status, and quality of life.
- Real-World Settings: Conduct trials in typical clinical settings to capture the complexities of routine care.
- Data Collection: Integrate data collection into routine clinical workflows to minimize disruption and improve data quality.
An Evolving Evidence Base
Recent work continues to examine how pragmatic trials can connect research questions with ordinary healthcare delivery. Reviews are likely to refine how investigators describe trial pragmatism, select designs, and assess applicability across settings. However, without a specified source base for this subsection, the direction and magnitude of recent developments cannot be stated precisely. The field should therefore be understood as evolving rather than settled.
Applicability Is Not Automatic
Including pragmatic elements in a trial does not guarantee that its findings will apply to every patient or healthcare setting. A JAMA example emphasizes that clinicians must examine the trial design when deciding whether results are likely to apply to their own patients. This places responsibility on readers to assess which pragmatic features were included and how closely the study context matches their practice. Pragmatic design can improve real-world relevance, but interpretation still requires attention to context.
Different Questions, Different Designs
Pragmatic clinical trials and hybrid effectiveness-implementation trials are related but answer different research questions. A review notes that most trials are neither purely pragmatic nor purely hybrid, while still identifying important differences between the two types. Comparative discussion also distinguishes pragmatic clinical trials from decentralized trials and considers their roles in addressing health equity gaps. These categories should therefore not be treated as interchangeable labels.
The Future of Clinical Trials: A Shift Towards Real-World Impact
The move towards pragmatic trials represents a significant shift in clinical research. By prioritizing external validity and real-world applicability, these trials can generate evidence that is more directly relevant to clinical decision-making and patient care.
Randomized Evidence in Real-World Settings
Pragmatic randomized controlled trials are presented as an important way to strengthen evidence used in healthcare decision-making. They preserve the insights associated with randomized controlled trials while aiming to capture the real-world effects of interventions. This combination can help connect methodological rigor with the conditions in which care is actually delivered. Their value lies in informing decisions without separating evidence generation entirely from everyday practice.
From Real-World Care to Regulatory Evidence
Future pragmatic trials are expected to continue testing interventions in diverse patient populations, typical healthcare settings, and everyday conditions. Their purpose is to inform clinical and policy decisions rather than only demonstrate effects under controlled laboratory conditions. Regulatory discussion is also focusing on pragmatic trials, real-world evidence approvals, the totality of evidence, and hybrid designs. These developments suggest closer integration between pragmatic research and regulatory decision-making.
Balancing Evidence and Healthcare Complexity
Pragmatic trials operate within healthcare systems that vary in patients, practices, resources, and decision-making needs. Their broader challenge is to produce useful evidence while preserving enough methodological rigor for confident interpretation. This balance may require compromises between experimental control and everyday applicability. Because no source material was provided for this subsection, these points should be treated as general framing rather than source-specific findings.
Evidence for Patients and Care Teams
Pragmatic trials aim to approximate everyday clinical practice and support decisions by patients, clinicians, and policymakers. Experiences from the PCORI-funded COMBINE, PREPARE, and REGAIN trials illustrate tradeoffs between explanatory and pragmatic perspectives when comparing treatment effectiveness in real-world contexts. Case studies describe pragmatic trials and embedded research as a bridge between controlled efficacy trials and real-world effectiveness assessments. Their human impact depends on making evidence relevant to the people and settings where care is delivered.
However, designing and conducting pragmatic trials requires careful consideration of several factors, including the intervention contrast, the clinical spectrum, the outcomes of interest, and the statistical analysis. Researchers need to make deliberate choices that align with the goal of producing evidence that is both rigorous and relevant.
As the healthcare landscape continues to evolve, pragmatic trials will play an increasingly important role in ensuring that medical interventions are effective, efficient, and patient-centered. The 'Pragmatic trials and real world evidence' series highlights the importance of integrating design options with practice, therefore this effort will push forward clinical research.